44 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
9 Jul 13
Regulation FD Disclosure
12:00am
community," TIG's objective is to share information with AASHTO member agencies, local agencies, and their industry partners to improve the Nation's
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
25 Feb 20
Processa Pharmaceuticals Provides Shareholder Update
9:30am
foundation to efficiently manage our drug development process, our Company on the NASDAQ market, and our visibility to the investment community
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities. These and other risks
424B5
ge7ejksyfbbva
20 Aug 21
Prospectus supplement for primary offering
4:46pm
PRE 14A
itpdbibsivtpze cb5d
1 Sep 21
Preliminary proxy
4:46pm
424B3
8srud5497
12 Apr 21
Prospectus supplement
1:44pm
424B5
dem21qi01
24 Mar 22
Prospectus supplement for primary offering
4:15pm
S-3
ve5vmi4 hccb3d
2 Apr 21
Shelf registration
12:00am
8-K
EX-10.1
xeu jiu24
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am